Pancreatic Cancer Research

ResearcherIRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'OrsolaActive in the last 2 years

Mariacristina Di Marco

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3470-9494; OpenAlex author ID A5047385429. Sources: OpenAlex.

Their work

Papers
33 (first author 2, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
124
Papers, trials and grants by year

2011: 2 papers · 2012: 1 paper · 2013: none · 2014: 1 paper · 2015: 2 papers · 2016: 1 paper · 2017: none · 2018: 4 papers · 2019: 1 paper · 2020: 4 papers · 2021: 4 papers · 2022: 3 papers · 2023: 4 papers · 2024: none · 2025: 2 papers · 2026: 4 papers

Papers 33

  1. Short-term versus long-course neoadjuvant chemotherapy for resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results f… Co-author DOI 10.1016/j.eclinm.2026.104190↗
  2. Impact of center-level protocol adherence on neoadjuvant treatment outcome in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejca.2026.117033↗
  3. Preoperative mFOLFIRINOX versus PAXG for stage I-III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the … Co-author DOI 10.1016/s0140-6736(25)01685-x↗
  4. Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes and AI-guided treatment selection. Co-author DOI 10.1093/oncolo/oyag085↗
  5. Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Variants. Co-author DOI 10.1002/cam4.70364↗
  6. Classic versus innovative strategies for immuno-therapy in pancreatic cancer. Co-author DOI 10.1016/j.addr.2025.115671↗
  7. Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary a… Co-author DOI 10.1016/j.esmoop.2022.100777↗
  8. Regret affects the choice between neoadjuvant therapy and upfront surgery for potentially resectable pancreatic cancer. Co-author DOI 10.1016/j.surg.2023.01.016↗
  9. Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv). Co-author DOI 10.1038/s41416-022-02086-w↗
  10. Comparative Effectiveness of Chemotherapy Alone Versus Radiotherapy-Based Regimens in Locally Advanced Pancreatic Cancer: A Real-World Multicenter Analysis (PA… Co-author DOI 10.3390/curroncol30060427↗
  11. Evolving knowledge in surgical oncology of pancreatic cancer: from theory to clinical practice-a fifteen-year journey at a tertiary referral centre. Co-author DOI 10.1007/s13304-022-01346-x↗
  12. Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes. Co-author DOI 10.3390/cancers14102429↗
  13. Molecular Characterization of Pancreatic Ductal Adenocarcinoma Using a Next-Generation Sequencing Custom-Designed Multigene Panel. Co-author DOI 10.3390/diagnostics12051058↗
  14. Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort. Co-author DOI 10.1016/j.esmoop.2020.100032↗
  15. Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter surve… First author DOI 10.1016/j.esmoop.2021.100238↗
  16. Neoadjuvant Therapy for Resectable Pancreatic Cancer: A New Standard of Care. Pooled Data From 3 Randomized Controlled Trials. Co-author DOI 10.1097/sla.0000000000005126↗
  17. Hacking Pancreatic Cancer: Present and Future of Personalized Medicine. Co-author DOI 10.3390/ph14070677↗
  18. Stereotactic body radiotherapy vs conventionally fractionated chemoradiation in locally advanced pancreatic cancer: A multicenter case-control study (PAULA-1). Co-author DOI 10.1002/cam4.3330↗
  19. Intraoperative electrochemotherapy in locally advanced pancreatic cancer: indications, techniques and results-a single-center experience. Co-author DOI 10.1007/s13304-020-00782-x↗
  20. Searching for novel multimodal treatments in oligometastatic pancreatic cancer. Last author DOI 10.1186/s12885-020-06718-3↗
  21. Higher Biologically Effective Dose Predicts Survival in SBRT of Pancreatic Cancer: A Multicentric Analysis (PAULA-1). Co-author DOI 10.21873/anticanres.13975↗
  22. Adjuvant chemoradiation in pancreatic cancer: impact of radiotherapy dose on survival. Co-author DOI 10.1186/s12885-019-5790-2↗
  23. β2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2017.11.007↗
  24. Organizing pneumonia after pancreatic cancer treatment with nab-paclitaxel and gemcitabine: a case report. Last author DOI 10.1259/bjrcr.20170086↗
  25. Evaluation of fatigue in patients with pancreatic cancer receiving chemotherapy treatment: a cross-sectional observational study. Co-author DOI 10.23750/abm.v89i4-s.7063↗
  26. Mutational burden of resectable pancreatic cancer, as determined by whole transcriptome and whole exome sequencing, predicts a poor prognosis. Last author DOI 10.3892/ijo.2018.4344↗
  27. State of the art biological therapies in pancreatic cancer. Co-author DOI 10.4251/wjgo.v8.i1.55↗
  28. Neoadjuvant Chemoradiotherapy and Surgery Versus Surgery Alone in Resectable Pancreatic Cancer: A Single-Center Prospective, Randomized, Controlled Trial Which… First author DOI 10.1007/s11605-015-2890-4↗
  29. Characterization of pancreatic ductal adenocarcinoma using whole transcriptome sequencing and copy number analysis by single-nucleotide polymorphism array. Co-author DOI 10.3892/mmr.2015.4344↗
  30. Antiprotease strategy in pancreatic cancer treatment: emergence from a preclinical study. Co-author DOI 10.1097/mpa.0b013e3182a6486e↗
  31. Hedgehog signaling: from the cuirass to the heart of pancreatic cancer. Co-author DOI 10.1016/j.pan.2012.06.001↗
  32. Pancreatic ductal adenocarcinoma associated with autoimmune pancreatitis. Co-author DOI 10.1159/000330291↗
  33. Chemotherapy followed by chemoradiotherapy in locally advanced pancreatic cancer: A literature review and report of two cases. Co-author DOI 10.3892/ol.2011.253↗

Closest collaborators

The 25 strongest of 124 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marina Macchini · 12 shared papers, 2011–2026 · strength 1.31
  2. Michele Reni · 8 shared papers, 2019–2026 · strength 1.18
  3. Letizia Procaccio · 6 shared papers, 2023–2026 · strength 1.13
  4. Giulia Orsi · 7 shared papers, 2021–2026 · strength 1.11
  5. Ilario Giovanni Rapposelli · 7 shared papers, 2021–2026 · strength 1.11
  6. Michèle Milella · 7 shared papers, 2021–2026 · strength 1.11
  7. Mario Scartozzi · 6 shared papers, 2021–2026 · strength 1.00
  8. Sara Lonardi · 5 shared papers, 2023–2026 · strength 0.92
  9. Riccardo Casadei · 12 shared papers, 2011–2022 · strength 0.91
  10. Giovanni Brandi · 7 shared papers, 2011–2025 · strength 0.81
  11. Massimo Falconi · 5 shared papers, 2019–2026 · strength 0.81
  12. Silvia Bozzarelli · 5 shared papers, 2021–2026 · strength 0.80
  13. Guido Giordano · 5 shared papers, 2021–2026 · strength 0.66
  14. Monica Niger · 5 shared papers, 2021–2026 · strength 0.66
  15. Giampaolo Tortora · 5 shared papers, 2021–2026 · strength 0.66
  16. Giuseppe Malleo · 3 shared papers, 2026 · strength 0.65
  17. Catia Carconi · 3 shared papers, 2026 · strength 0.65
  18. Carla Serra · 8 shared papers, 2011–2022 · strength 0.62
  19. Francesca Bergamo · 3 shared papers, 2025–2026 · strength 0.58
  20. Elisa Giommoni · 4 shared papers, 2021–2026 · strength 0.57
  21. Claudio Ricci · 7 shared papers, 2015–2021 · strength 0.55
  22. Francesco Minni · 7 shared papers, 2015–2022 · strength 0.55
  23. Enrico Vasile · 3 shared papers, 2023–2026 · strength 0.48
  24. Maria Grazia Rodriquenz · 4 shared papers, 2021–2025 · strength 0.46
  25. Stefano Cascinu · 4 shared papers, 2021–2025 · strength 0.46

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.